Vietnamese Journal of Neurology

Article detail

Article detail description

Home
Articles Issue: Vietnamese Journal of Neurology No.39 Tổng quan

Guidelines for the diagnosis and treatment of multiple sclerosis

Published: November 20, 2023
Views: 4

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, characterized by chronic inflammation, demyelination (loss of myelin sheath), nerve fiber loss, and potential relapses or progression. Demyelinated patches often develop at different times and in different locations within the central nervous system (spatially and temporally scattered).

Symptoms and neurological signs are manifestations of the damage and spread of demyelinated lesions, primarily occurring in the white matter of the brain, spinal cord, or optic nerves.

References

1.
Cree BAC, Hauser SL. Multiple Sclerosis,. Harrison's Principles of Internal Medicine, . 20 ed. McGraw-Hill Education: New York, NY.; 2018.
2.
MS International Federation. Atlas of MS 3rd edition. Part 1: Mapping multiple sclerosis around the world epidemiology findings. https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf. 2020.
3.
Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14(2): 183-93.
4.
Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 2021; 14: 17562864211039648.
5.
Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol 2014; 72 Suppl 1: 1-5.
6.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
7.
The National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. NICE guideline. https://www.nice.org.uk/terms-andconditions#notice-of-rights) 2022
8.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-73.
9.
Baskaran AB, Grebenciucova E, Shoemaker T, Graham EL. Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist. J Clin Neurol 2023; 19(3): 217-29.
10.
Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. Handb Clin Neurol 2014; 122: 513-62.
11.
Lim EC, Seet RC. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol 2010; 6(11): 624-36.
12.
World health Organization. Proposal for inclusion of multiple sclerosis disease-modifying therapies (DMTs) on the complementary WHO Model Lists of Essential Medicines. World health Organization. 2022.
13.
Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord 2020; 37: 101459.
14.
Wise J. Multiple sclerosis: NICE recommends treatment for secondary progressive MS. BMJ 2020; 371: m3990.
15.
Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med 2020; 133(12): 1380-90 e2.
16.
Zéphir H, Durand-Dubief F, Le -Page E. Fiches pratiques thérapeutiques pour la prise en charge des patients atteints de sclérose en plaques. Practical treatment sheets for multiple sclerosis. Pratique Neurologique 2023; 14(2):: 98-107.
17.
Limmroth V. Treatment of relapsing-remitting multiple sclerosis: current and future algorithms. Eur Neurol 2014; 72 Suppl 1: 35-8.
18.
Carod-Artal FJ, Adjamian P, Vila Silvan C, Bagul M, Gasperini C. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. Expert Rev Neurother 2022; 22(6): 499-511.
19.
Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 2018; 24(12): 1594-604.
20.
Lee M, O'Brien P. Pregnancy and multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79(12): 1308-11.
21.
Reeve K, On BI, Havla J, et al. Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database Syst Rev 2023; 9(9): CD013606.
22.
Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90(17): 777-88.
23.
The National Institute for Health and Care Excellence. Cladribine for treating relapsing–remitting multiple sclerosis. NICE guideline. https://www.nice.org.uk/guidance/ta616). 2019.
24.
Dargahi N, Katsara M, Tselios T, et al. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci 2017; 7(7).
25.
Ministry of Health Malaysia. Management of multiple sclerosis. Clinical practice guidelines MOH/P/PAK/293.15(GU). 2015.
26.
Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 2018; 25(2): 215-37.
27.
Thompson AJ. Commentary on the ECTRIMS-EAN guideline for pharmacological treatment of multiple sclerosis. Ther Adv Neurol Disord 2018; 11: 1756286418770378.
28.
Nonino F, Baldin E, Ridley B, Casetta I, Iuliano G, G. F. Azathioprine for people with multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No.: CD015005. DOI: 10.1002/14651858.CD015005.
29.
Ramo-Tello C, Blanco Y, Brieva L, et al. Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses. J Pers Med 2021; 12(1).
30.
Coyle PK. Multiple sclerosis in pregnancy. Continuum (Minneap Minn) 2014; 20(1 Neurology of Pregnancy): 42-59.
31.
Multiple Sclerosis International Federation. MSIF's Off-Label Treatments recommendations for low-resource settings. https://www.msif.org/molt-guidelines-azathioprine-rituximab/. 2023.
32.
Multiple Sclerosis International Federation. MSIF Essential Medicines Panel (MEMP) Guidelines for essential disease-modifying therapies for multiple sclerosis for low-resource settings. https://www.msif.org/wp-content/uploads/2023/01/MEMP_EtD-and-recommendations_public_201222.pdf. 2023.
33.
Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95(2): 284-92.
34.
Miller AE, Chitnis T, Cohen BA, et al. Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society. JAMA Neurol 2021; 78(2): 241-6.

Authors

  • Nguyen Van Tuan
  • Vo Hong Khoi
  • Le Van Tuan
  • Nguyen Hong Quan
  • Dinh Huynh To Huong
  • Hoang Tien Trong Nghia
  • Le Van Thuy
  • Hoang Thi Thanh Thuy
  • Nguyen Huu Cong

Files

PDF
Article Views4
Document Views3
Downloads2
Section Articles
Issue Vietnamese Journal of Neurology No.39
Category Tổng quan

Related articles section label

Related articles

Related articles category hint

More articles

Trigeminal autonomic cephalalgias

Trigeminal Autonomic Cephalalgias (TACs) are characterized by the presence of autonomic symptoms during headache attacks. The most common symptoms include rhinorrhea, nasal congestion, conjunctival injection, and lacrima...

Chi tiết bài báo
5
Vo The Nhan; Vo Hong Khoi